Our data shows that both ALK4/5 receptor inhibition and LONG R3 IGF-I analogues enhance C2C12 skeletal muscle cell differentiation in vitro, successfully limit cancer cachexia in vivo, and down-regulates the associated target genes. Here, IGF1 is linked to cancer.